Jenscare Scientific (HKG:9877) said the success rate for its LuX-Valve Plus transcatheter tricuspid valve replacement device, tested during a 30-day global follow-up study, reached 97%, according to a Friday filing with the Hong Kong bourse.
The study, performed on 161 patients in 20 centers worldwide, also showed good safety and performance of the device, the filing said.
Meanwhile, Jenscare's JensClip transcatheter mitral valve repair system showed a device operation success rate of 95% during its one-year follow-up study in China, the filing said.
Jenscare performed the study on 114 patients with an average age of 71 years across 18 centers in China.
Jenscare presented the results of the 30-day study during the EuroPCR 2025 in Paris.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。